D
David A. Quigley
Researcher at University of California, San Francisco
Publications - 87
Citations - 3467
David A. Quigley is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 27, co-authored 65 publications receiving 2426 citations. Previous affiliations of David A. Quigley include The Breast Cancer Research Foundation & Oslo University Hospital.
Papers
More filters
Journal ArticleDOI
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
David A. Quigley,Ha X. Dang,Shuang G. Zhao,Paul Lloyd,Rahul Aggarwal,Joshi J. Alumkal,Adam Foye,Vishal Kothari,Marc D. Perry,Adina M. Bailey,Denise Playdle,Travis J. Barnard,Li Zhang,Jin Zhang,Jack F. Youngren,Marcin Cieslik,Abhijit Parolia,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Nathan A. Lack,Amina Zoubeidi,Robert E. Reiter,Robert E. Reiter,Matthew Rettig,Owen N. Witte,Charles J. Ryan,Lawrence Fong,Won Kim,Terence W. Friedlander,Jonathan Chou,Haolong Li,Rajdeep Das,Hui Li,Ruhollah Moussavi-Baygi,Hani Goodarzi,Luke A. Gilbert,Primo N. Lara,Christopher P. Evans,Theodore C. Goldstein,Theodore C. Goldstein,Joshua M. Stuart,Scott A. Tomlins,Daniel E. Spratt,R. Keira Cheetham,Donavan T. Cheng,Kyle Kai-How Farh,Julian S. Gehring,Jörg Hakenberg,Arnold Liao,P. G. Febbo,John Shon,Brad Sickler,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Jiaoti Huang,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,Felix Y. Feng +64 more
TL;DR: Integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches, providing a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
Journal ArticleDOI
The mutational landscapes of genetic and chemical models of Kras -driven lung cancer
Peter M. K. Westcott,Kyle D. Halliwill,Minh D. To,Mamunur Rashid,Alistair G. Rust,Thomas M. Keane,Reyno Delrosario,Kuang-Yu Jen,Kay E. Gurley,Christopher J. Kemp,Erik Fredlund,David A. Quigley,David J. Adams,Allan Balmain +13 more
TL;DR: This article performed whole-exome sequencing on adenomas from three mouse models of non-small-cell lung cancer, which were induced either by exposure to carcinogens (methyl-nitrosourea (MNU) and urethane) or by genetic activation of Kras (Kras(LA2).
Journal ArticleDOI
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Laxmi Silwal-Pandit,Hans Kristian Moen Vollan,Suet-Feung Chin,Oscar M. Rueda,Steven McKinney,Tomo Osako,David A. Quigley,Vessela N. Kristensen,Samuel Aparicio,Anne Lise Børresen-Dale,Carlos Caldas,Anita Langerød +11 more
TL;DR: This study reveals that TP53 mutations have different clinical relevance in molecular subtypes of breast cancer, and suggests diverse roles for TP53 in the biology underlying breast cancer development.
Journal ArticleDOI
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
David A. Quigley,Joshi J. Alumkal,Alexander W. Wyatt,Vishal Kothari,Adam Foye,Paul Lloyd,Rahul Aggarwal,Won Kim,Eric Lu,Jacob Schwartzman,Kevin Beja,Matti Annala,Rajdeep Das,Morgan E. Diolaiti,Colin C. Pritchard,George Thomas,Scott A. Tomlins,Karen E. Knudsen,Christopher J. Lord,Charles J. Ryan,Jack F. Youngren,Tomasz M. Beer,Alan Ashworth,Eric J. Small,Felix Y. Feng +24 more
TL;DR: BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib are identified and it is shown that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PAR Pi resistance.
Journal ArticleDOI
The DNA methylation landscape of advanced prostate cancer
Shuang G. Zhao,Shuang G. Zhao,William S. Chen,William S. Chen,Haolong Li,Adam Foye,Meng Zhang,Martin Sjöström,Rahul Aggarwal,Denise Playdle,Arnold Liao,Joshi J. Alumkal,Rajdeep Das,Jonathan Chou,Junjie Tony Hua,Travis J. Barnard,Adina M. Bailey,Eric D. Chow,Marc D. Perry,Ha X. Dang,Rendong Yang,Ruhollah Moussavi-Baygi,Li Zhang,Mohammed Alshalalfa,S. Laura Chang,Kathleen E. Houlahan,Kathleen E. Houlahan,Kathleen E. Houlahan,Yu Jia Shiah,Tomasz M. Beer,George Thomas,Kim N. Chi,Martin E. Gleave,Amina Zoubeidi,Robert E. Reiter,Matthew Rettig,Matthew Rettig,Owen N. Witte,M. Yvonne Kim,Lawrence Fong,Daniel E. Spratt,Todd M. Morgan,Rohit Bose,Franklin W. Huang,Hui Li,Lisa N. Chesner,Tanushree R. Shenoy,Hani Goodarzi,Irfan A. Asangani,Shahneen Sandhu,Joshua M. Lang,Nupam P. Mahajan,Primo N. Lara,Christopher P. Evans,Phillip G. Febbo,Serafim Batzoglou,Karen E. Knudsen,Housheng Hansen He,Housheng Hansen He,Jiaoti Huang,Wilbert Zwart,Joseph F. Costello,Jianhua Luo,Scott A. Tomlins,Alexander W. Wyatt,Scott M. Dehm,Alan Ashworth,Luke A. Gilbert,Paul C. Boutros,Paul C. Boutros,Kyle Kai-How Farh,Arul M. Chinnaiyan,Christopher G. Maher,Eric J. Small,David A. Quigley,Felix Y. Feng +75 more
TL;DR: This study identifies genomic regions that are differentially methylated during disease progression and a novel epigenomic subtype and shows that differential methylation during progression preferentially occurs at somatic mutational hotspots and putative regulatory regions.